Germline BRCA2-mutant prostate cancers harbor a twofold higher percentage of genomic aletrations, graeter somatic single-nucleotide variant and increased CAN burden compared to localized sporadic prostate tumors [30,418]. The gene discussed is BRCA2; the disease is Familial prostate cancer.